 | • レポートコード：GIR-2104Z01012 • 出版社/出版日：GlobalInfoResearch / 2021年4月 ※2025年版があります。お問い合わせください。 • レポート形態：英文、PDF、100ページ • 納品方法：Eメール（納期：2~3日） • 産業分類：医療・医薬品 |
| Single User | ￥504,600 (USD3,480) | ▷ お問い合わせ |
| Multi User | ￥756,900 (USD5,220) | ▷ お問い合わせ |
| Corporate User | ￥1,009,200 (USD6,960) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査資料では、アンチセンス・RNAi治療のグローバル市場について調査・分析し、2021年から2026年までの市場予測をまとめております。アンチセンス・RNAi治療の種類別市場規模（RNA干渉、アンチセンスRNA）、用途別市場規模（病院、診療所）、地域別市場規模（北米、アメリカ、ヨーロッパ、アジア、中国、日本、東南アジア、南米、中東、アフリカなど）、市場動向、企業別販売量と市場シェア、販売チャネルなどの情報を掲載しています。 ・アンチセンス・RNAi治療の市場概要 ・企業情報（企業概要、製品概要、販売量、価格、売上）：Tekmira Pharmaceuticals、Arbutus Biopharma、Alnylam Pharmaceuticals、Antisense Therapeutics、Silence Therapeutics、Isis Pharmaceuticals、Sirnaomics、Santaris、Roche ・企業別市場シェア ・地域別市場分析2016年-2026年 ・種類別分析2016年-2026年：RNA干渉、アンチセンスRNA ・用途別分析2016年-2026年：病院、診療所 ・アンチセンス・RNAi治療の北米市場規模2016年-2026年：アメリカ、カナダ、メキシコ ・アンチセンス・RNAi治療のヨーロッパ市場規模2016年-2026年：ドイツ、イギリス、フランス、ロシア、イタリア ・アンチセンス・RNAi治療のアジア市場規模2016年-2026年：中国、日本、韓国、インド、東南アジア、オーストラリア ・アンチセンス・RNAi治療の南米市場規模2016年-2026年：ブラジル、アルゼンチン ・アンチセンス・RNAi治療の中東・アフリカ市場規模2016年-2026年：サウジアラビア、トルコ、エジプト、南アフリカ ・販売チャネル、流通業者・代理店、顧客リスト ・調査の結果・結論 |
The Antisense and RNAi Therapeutics market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our latest research, the global Antisense and RNAi Therapeutics size is estimated to be USD xx million in 2025 from USD xx million in 2019, with a change XX% between 2019 and 2020. The global Antisense and RNAi Therapeutics market size is expected to grow at a CAGR of xx% for the next five years.
Market segmentation
Antisense and RNAi Therapeutics market is split by Type and by Application. For the period 2016-2026, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
RNA Interference
Antisense RNA
Market segment by Application, can be divided into
Hospital
Clinic
Market segment by players, this report covers
Tekmira Pharmaceuticals
Arbutus Biopharma
Alnylam Pharmaceuticals
Antisense Therapeutics
Silence Therapeutics
Isis Pharmaceuticals
Sirnaomics
Santaris
Roche
Market segment by regions, regional analysis covers
North America (United States, Canada, and Mexico)
Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
South America (Brazil, Argentina, Rest of South America)
Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
1 Market Overview
1.1 Product Overview and Scope of Antisense and RNAi Therapeutics
1.2 Classification of Antisense and RNAi Therapeutics by Type
1.2.1 Overview: Global Antisense and RNAi Therapeutics Market Size by Type: 2020 Versus 2021 Versus 2026
1.2.2 Global Antisense and RNAi Therapeutics Revenue Market Share by Type in 2020
1.2.3 RNA Interference
1.2.4 Antisense RNA
1.3 Global Antisense and RNAi Therapeutics Market by Application
1.3.1 Overview: Global Antisense and RNAi Therapeutics Market Size by Application: 2020 Versus 2021 Versus 2026
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Antisense and RNAi Therapeutics Market Size & Forecast
1.5 Global Antisense and RNAi Therapeutics Market Size and Forecast by Region
1.5.1 Global Antisense and RNAi Therapeutics Market Size by Region: 2016 VS 2021 VS 2026
1.5.2 Global Antisense and RNAi Therapeutics Market Size by Region, (2016-2021)
1.5.3 North America Antisense and RNAi Therapeutics Market Size and Prospect (2016-2026)
1.5.4 Europe Antisense and RNAi Therapeutics Market Size and Prospect (2016-2026)
1.5.5 Asia-Pacific Antisense and RNAi Therapeutics Market Size and Prospect (2016-2026)
1.5.6 South America Antisense and RNAi Therapeutics Market Size and Prospect (2016-2026)
1.5.7 Middle East and Africa Antisense and RNAi Therapeutics Market Size and Prospect (2016-2026)
1.6 Market Drivers, Restraints and Trends
1.6.1 Antisense and RNAi Therapeutics Market Drivers
1.6.2 Antisense and RNAi Therapeutics Market Restraints
1.6.3 Antisense and RNAi Therapeutics Trends Analysis
2 Company Profiles
2.1 Tekmira Pharmaceuticals
2.1.1 Tekmira Pharmaceuticals Details
2.1.2 Tekmira Pharmaceuticals Major Business
2.1.3 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
2.1.4 Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.1.5 Tekmira Pharmaceuticals Recent Developments and Future Plans
2.2 Arbutus Biopharma
2.2.1 Arbutus Biopharma Details
2.2.2 Arbutus Biopharma Major Business
2.2.3 Arbutus Biopharma Antisense and RNAi Therapeutics Product and Solutions
2.2.4 Arbutus Biopharma Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.2.5 Arbutus Biopharma Recent Developments and Future Plans
2.3 Alnylam Pharmaceuticals
2.3.1 Alnylam Pharmaceuticals Details
2.3.2 Alnylam Pharmaceuticals Major Business
2.3.3 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
2.3.4 Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.3.5 Alnylam Pharmaceuticals Recent Developments and Future Plans
2.4 Antisense Therapeutics
2.4.1 Antisense Therapeutics Details
2.4.2 Antisense Therapeutics Major Business
2.4.3 Antisense Therapeutics Antisense and RNAi Therapeutics Product and Solutions
2.4.4 Antisense Therapeutics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.4.5 Antisense Therapeutics Recent Developments and Future Plans
2.5 Silence Therapeutics
2.5.1 Silence Therapeutics Details
2.5.2 Silence Therapeutics Major Business
2.5.3 Silence Therapeutics Antisense and RNAi Therapeutics Product and Solutions
2.5.4 Silence Therapeutics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.5.5 Silence Therapeutics Recent Developments and Future Plans
2.6 Isis Pharmaceuticals
2.6.1 Isis Pharmaceuticals Details
2.6.2 Isis Pharmaceuticals Major Business
2.6.3 Isis Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
2.6.4 Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.6.5 Isis Pharmaceuticals Recent Developments and Future Plans
2.7 Sirnaomics
2.7.1 Sirnaomics Details
2.7.2 Sirnaomics Major Business
2.7.3 Sirnaomics Antisense and RNAi Therapeutics Product and Solutions
2.7.4 Sirnaomics Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.7.5 Sirnaomics Recent Developments and Future Plans
2.8 Santaris
2.8.1 Santaris Details
2.8.2 Santaris Major Business
2.8.3 Santaris Antisense and RNAi Therapeutics Product and Solutions
2.8.4 Santaris Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.8.5 Santaris Recent Developments and Future Plans
2.9 Roche
2.9.1 Roche Details
2.9.2 Roche Major Business
2.9.3 Roche Antisense and RNAi Therapeutics Product and Solutions
2.9.4 Roche Antisense and RNAi Therapeutics Revenue, Gross Margin and Market Share (2019-2021)
2.9.5 Roche Recent Developments and Future Plans
3 Market Competition, by Players
3.1 Global Antisense and RNAi Therapeutics Revenue and Share by Players (2019-2021)
3.2 Market Concentration Rate
3.2.1 Top 5 Antisense and RNAi Therapeutics Players Market Share
3.2.2 Top 10 Antisense and RNAi Therapeutics Players Market Share
3.2.3 Market Competition Trend
3.3 Antisense and RNAi Therapeutics Players Head Office, Products and Services Provided
3.4 Mergers & Acquisitions
3.5 New Entrants and Expansion Plans
4 Market Size Segment by Type
4.1 Global Antisense and RNAi Therapeutics Revenue and Market Share by Type (2016-2021)
4.2 Global Antisense and RNAi Therapeutics Market Forecast by Type (2021-2026)
5 Market Size Segment by Application
5.1 Global Antisense and RNAi Therapeutics Revenue Market Share by Application (2016-2021)
5.2 Antisense and RNAi Therapeutics Market Forecast by Application (2021-2026)
6 North America by Country, by Type, and by Application
6.1 North America Antisense and RNAi Therapeutics Revenue by Type (2016-2026)
6.2 North America Antisense and RNAi Therapeutics Revenue by Application (2016-2026)
6.3 North America Antisense and RNAi Therapeutics Market Size by Country
6.3.1 North America Antisense and RNAi Therapeutics Revenue by Country (2016-2026)
6.3.2 United States Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
6.3.3 Canada Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
6.3.4 Mexico Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
7 Europe by Country, by Type, and by Application
7.1 Europe Antisense and RNAi Therapeutics Revenue by Type (2016-2026)
7.2 Europe Antisense and RNAi Therapeutics Revenue by Application (2016-2026)
7.3 Europe Antisense and RNAi Therapeutics Market Size by Country
7.3.1 Europe Antisense and RNAi Therapeutics Revenue by Country (2016-2026)
7.3.2 Germany Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
7.3.3 France Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
7.3.4 United Kingdom Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
7.3.5 Russia Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
7.3.6 Italy Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
8 Asia-Pacific by Region, by Type, and by Application
8.1 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Type (2016-2026)
8.2 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Application (2016-2026)
8.3 Asia-Pacific Antisense and RNAi Therapeutics Market Size by Region
8.3.1 Asia-Pacific Antisense and RNAi Therapeutics Revenue by Region (2016-2026)
8.3.2 China Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
8.3.3 Japan Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
8.3.4 South Korea Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
8.3.5 India Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
8.3.6 Southeast Asia Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
8.3.7 Australia Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
9 South America by Country, by Type, and by Application
9.1 South America Antisense and RNAi Therapeutics Revenue by Type (2016-2026)
9.2 South America Antisense and RNAi Therapeutics Revenue by Application (2016-2026)
9.3 South America Antisense and RNAi Therapeutics Market Size by Country
9.3.1 South America Antisense and RNAi Therapeutics Revenue by Country (2016-2026)
9.3.2 Brazil Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
9.3.3 Argentina Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
10 Middle East & Africa by Country, by Type, and by Application
10.1 Middle East & Africa Antisense and RNAi Therapeutics Revenue by Type (2016-2026)
10.2 Middle East & Africa Antisense and RNAi Therapeutics Revenue by Application (2016-2026)
10.3 Middle East & Africa Antisense and RNAi Therapeutics Market Size by Country
10.3.1 Middle East & Africa Antisense and RNAi Therapeutics Revenue by Country (2016-2026)
10.3.2 Turkey Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
10.3.3 Saudi Arabia Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
10.3.4 UAE Antisense and RNAi Therapeutics Market Size and Forecast (2016-2026)
11 Research Findings and Conclusion
12 Appendix
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
Table 1. Global Antisense and RNAi Therapeutics Revenue by Type, (USD Million), 2020 VS 2021 VS 2026
Table 2. Global Antisense and RNAi Therapeutics Revenue by Application, (USD Million), 2020 VS 2021 VS 2026
Table 3. Global Market Antisense and RNAi Therapeutics Revenue (Million USD) Comparison by Region (2016 VS 2021 VS 2026)
Table 4. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Region (2016-2021)
Table 5. Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2021-2026)
Table 6. Tekmira Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 7. Tekmira Pharmaceuticals Major Business
Table 8. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 9. Tekmira Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 10. Arbutus Biopharma Corporate Information, Head Office, and Major Competitors
Table 11. Arbutus Biopharma Major Business
Table 12. Arbutus Biopharma Antisense and RNAi Therapeutics Product and Solutions
Table 13. Arbutus Biopharma Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 14. Alnylam Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 15. Alnylam Pharmaceuticals Major Business
Table 16. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 17. Alnylam Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 18. Antisense Therapeutics Corporate Information, Head Office, and Major Competitors
Table 19. Antisense Therapeutics Major Business
Table 20. Antisense Therapeutics Antisense and RNAi Therapeutics Product and Solutions
Table 21. Antisense Therapeutics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 22. Silence Therapeutics Corporate Information, Head Office, and Major Competitors
Table 23. Silence Therapeutics Major Business
Table 24. Silence Therapeutics Antisense and RNAi Therapeutics Product and Solutions
Table 25. Silence Therapeutics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 26. Isis Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 27. Isis Pharmaceuticals Major Business
Table 28. Isis Pharmaceuticals Antisense and RNAi Therapeutics Product and Solutions
Table 29. Isis Pharmaceuticals Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 30. Sirnaomics Corporate Information, Head Office, and Major Competitors
Table 31. Sirnaomics Major Business
Table 32. Sirnaomics Antisense and RNAi Therapeutics Product and Solutions
Table 33. Sirnaomics Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 34. Santaris Corporate Information, Head Office, and Major Competitors
Table 35. Santaris Major Business
Table 36. Santaris Antisense and RNAi Therapeutics Product and Solutions
Table 37. Santaris Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 38. Roche Corporate Information, Head Office, and Major Competitors
Table 39. Roche Major Business
Table 40. Roche Antisense and RNAi Therapeutics Product and Solutions
Table 41. Roche Antisense and RNAi Therapeutics Revenue (USD Million), Gross Margin and Market Share (2019-2021)
Table 42. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Players (2019-2021)
Table 43. Global Antisense and RNAi Therapeutics Revenue Share by Players (2019-2021)
Table 44. Breakdown of Antisense and RNAi Therapeutics by Company Type (Tier 1, Tier 2 and Tier 3)
Table 45. Antisense and RNAi Therapeutics Players Head Office, Products and Services Provided
Table 46. Antisense and RNAi Therapeutics Mergers & Acquisitions in the Past Five Years
Table 47. Antisense and RNAi Therapeutics New Entrants and Expansion Plans
Table 48. Global Antisense and RNAi Therapeutics Revenue (USD Million) by Type (2016-2021)
Table 49. Global Antisense and RNAi Therapeutics Revenue Share by Type (2016-2021)
Table 50. Global Antisense and RNAi Therapeutics Revenue Forecast by Type (2021-2026)
Table 51. Global Antisense and RNAi Therapeutics Revenue by Application (2016-2021)
Table 52. Global Antisense and RNAi Therapeutics Revenue Forecast by Application (2021-2026)
Table 53. North America Antisense and RNAi Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 54. North America Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 55. North America Antisense and RNAi Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 56. North America Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 57. North America Antisense and RNAi Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 58. North America Antisense and RNAi Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 59. Europe Antisense and RNAi Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 60. Europe Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 61. Europe Antisense and RNAi Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 62. Europe Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 63. Europe Antisense and RNAi Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 64. Europe Antisense and RNAi Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 65. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 66. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 67. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 68. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 69. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Region (2016-2021) & (USD Million)
Table 70. Asia-Pacific Antisense and RNAi Therapeutics Revenue by Region (2021-2026) & (USD Million)
Table 71. South America Antisense and RNAi Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 72. South America Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 73. South America Antisense and RNAi Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 74. South America Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 75. South America Antisense and RNAi Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 76. South America Antisense and RNAi Therapeutics Revenue by Country (2021-2026) & (USD Million)
Table 77. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Type (2016-2021) & (USD Million)
Table 78. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Type (2021-2026) & (USD Million)
Table 79. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Application (2016-2021) & (USD Million)
Table 80. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Application (2021-2026) & (USD Million)
Table 81. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Country (2016-2021) & (USD Million)
Table 82. Middle East & Africa Antisense and RNAi Therapeutics Revenue by Country (2021-2026) & (USD Million)
List of Figures
Figure 1. Antisense and RNAi Therapeutics Picture
Figure 2. Global Antisense and RNAi Therapeutics Revenue Market Share by Type in 2020
Figure 3. RNA Interference
Figure 4. Antisense RNA
Figure 5. Antisense and RNAi Therapeutics Revenue Market Share by Application in 2020
Figure 6. Hospital Picture
Figure 7. Clinic Picture
Figure 8. Global Antisense and RNAi Therapeutics Revenue, (USD Million): 2020 VS 2021 VS 2026
Figure 9. Global Antisense and RNAi Therapeutics Revenue and Forecast (2016-2026) & (USD Million)
Figure 10. Global Antisense and RNAi Therapeutics Revenue Market Share by Region (2016-2026)
Figure 11. Global Antisense and RNAi Therapeutics Revenue Market Share by Region in 2020
Figure 12. North America Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 13. Europe Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 14. Asia-Pacific Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 15. South America Antisense and RNAi Therapeutics Revenue (USD Million) and Growth Rate (2016-2026)
Figure 16. Antisense and RNAi Therapeutics Market Drivers
Figure 17. Antisense and RNAi Therapeutics Market Restraints
Figure 18. Antisense and RNAi Therapeutics Market Trends
Figure 19. Tekmira Pharmaceuticals Recent Developments and Future Plans
Figure 20. Arbutus Biopharma Recent Developments and Future Plans
Figure 21. Alnylam Pharmaceuticals Recent Developments and Future Plans
Figure 22. Antisense Therapeutics Recent Developments and Future Plans
Figure 23. Silence Therapeutics Recent Developments and Future Plans
Figure 24. Isis Pharmaceuticals Recent Developments and Future Plans
Figure 25. Sirnaomics Recent Developments and Future Plans
Figure 26. Santaris Recent Developments and Future Plans
Figure 27. Roche Recent Developments and Future Plans
Figure 29. Global Antisense and RNAi Therapeutics Revenue Share by Players in 2020
Figure 30. Antisense and RNAi Therapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
Figure 31. Global Top 3 Players Antisense and RNAi Therapeutics Revenue Market Share in 2020
Figure 32. Global Top 10 Players Antisense and RNAi Therapeutics Revenue Market Share in 2020
Figure 33. Key Players Market Share Trend (Top 3 Market Share: 2019 VS 2020 VS 2021)
Figure 34. Global Antisense and RNAi Therapeutics Revenue Share by Type in 2020
Figure 35. Global Antisense and RNAi Therapeutics Market Share Forecast by Type (2021-2026)
Figure 36. Global Antisense and RNAi Therapeutics Revenue Share by Application in 2020
Figure 37. Global Antisense and RNAi Therapeutics Market Share Forecast by Application (2021-2026)
Figure 38. North America Antisense and RNAi Therapeutics Sales Market Share by Type (2016-2026)
Figure 39. North America Antisense and RNAi Therapeutics Sales Market Share by Application (2016-2026)
Figure 40. North America Antisense and RNAi Therapeutics Revenue Market Share by Country (2016-2026)
Figure 41. United States Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 42. Canada Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 43. Mexico Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 44. Europe Antisense and RNAi Therapeutics Sales Market Share by Type (2016-2026)
Figure 45. Europe Antisense and RNAi Therapeutics Sales Market Share by Application (2016-2026)
Figure 46. Europe Antisense and RNAi Therapeutics Revenue Market Share by Country (2016-2026)
Figure 47. Germany Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 48. France Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 49. United Kingdom Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 50. Russia Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 51. Italy Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 52. Asia-Pacific Antisense and RNAi Therapeutics Sales Market Share by Type (2016-2026)
Figure 53. Asia-Pacific Antisense and RNAi Therapeutics Sales Market Share by Application (2016-2026)
Figure 54. Asia-Pacific Antisense and RNAi Therapeutics Revenue Market Share by Region (2016-2026)
Figure 55. China Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 56. Japan Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 57. South Korea Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 58. India Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 59. Southeast Asia Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 60. Australia Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 61. South America Antisense and RNAi Therapeutics Sales Market Share by Type (2016-2026)
Figure 62. South America Antisense and RNAi Therapeutics Sales Market Share by Application (2016-2026)
Figure 63. South America Antisense and RNAi Therapeutics Revenue Market Share by Country (2016-2026)
Figure 64. Brazil Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 65. Argentina Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 66. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Type (2016-2026)
Figure 67. Middle East and Africa Antisense and RNAi Therapeutics Sales Market Share by Application (2016-2026)
Figure 68. Middle East and Africa Antisense and RNAi Therapeutics Revenue Market Share by Country (2016-2026)
Figure 69. Turkey Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 70. Saudi Arabia Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 71. UAE Antisense and RNAi Therapeutics Revenue and Growth Rate (2016-2026) & (USD Million)
Figure 72. Methodology
Figure 73. Research Process and Data Source
世界のアンチセンス・RNAi治療市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Antisense and RNAi Therapeutics Market The global Antisense and RNAi Therapeutics market size is projected to reach US$ XX million by 2026, from US$ XX million in 2019, at a CAGR of XX% during 2021-2026. With industry-standard accuracy in analysis and high data i…- 世界のアンチセンス・RNAi治療市場規模・現状・予測（2021年-2027年） Antisense therapy is a form of treatment for genetic disorders or infections. When the genetic sequence of a particular gene is known to be causative of a particular disease, it is possible to synthesize a strand of nucleic acid (DNA, RNA or a chemical analogue) that will bind to the messenger RNA (…
- 世界の治療用RNAi市場規模・現状・予測（2021年-2027年） RNA interference (RNAi) is a biological process in which RNA molecules inhibit gene expression, typically by causing the destruction of specific mRNA molecules. Historically, it was known by other names, including co-suppression, post-transcriptional gene silencing (PTGS), and quelling. Only after t…
- 世界のオリゴヌクレオチド治療薬市場規模・現状・予測（2021年-2027年） Many pharmaceutical companies were conducting research on oligonucleotide therapy, which employs chemically synthesized nucleotide-like small molecule drugs with potential specificity similar to that of therapeutic antibodies. Although several types of oligonucleotide therapies exist, five of them a…
- 世界のオリゴヌクレオチドベース治療法市場規模・現状・予測（2021年-2027年） Market Analysis and Insights: Global Oligonucleotide-based Therapies Market The global Oligonucleotide-based Therapies market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027. With industry-standard accuracy in analysis and high data i…